Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds

O. S. Sohn, H. Li, A. Surace, Karam El-Bayoumy, P. Upadhyaya, E. S. Fiala

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We previously demonstrated that while both benzyl selenocyanate (BSC) and 1,4- phenylenebis(methylene)selenocyanate (p-XSC) have high efficacy as cancer chemo-preventive agents in several animal tumor models, p-XSC is less toxic. Using atomic absorption spectophotometry, we compared the urinary and fecal excretion of total selenium derived from pXSC and BSC in female CD rats. The results indicate that there exist distinct differences in the selenium excretion patterns when these compounds are administered orally, but not when they are administered ip. In terms of the percent dose, the total selenium excreted in the 5 days following equimolar dosing (50 μmol/ikgl of p-XSC or BSC, respectively, was as follows: after gavage, 68% or 3% in the feces and 6% or 18% in the urine; after ip. administration, 9% or 4% in feces and 16% or 20% in urine. These results indicate that while most of the BSC administered orally is absorbed in the gastrointestinal tract, most of the p-XSC given the same way is not absorbed. This difference would account for the significantly lower tissue levels of selenium derived from orally administered p-XSC compared to BSC, and accounts, in part, for the lower oral toxicity of p-XSC compared to BSC. Subsequent studies employing o- and m-XSC, isomers of p-XSC, demonstrate that the excretion patterns of selenium are significantly different, depending on the position of substitution. In vitro studies suggest that the differences among BSC and the three XSC isomers with regard to absorption is probably due to different extent of binding to components of the gut contents. The results of these studies are useful for the future design of less toxic and more effective chemo-preventive organic seleno-cyanates.

Original languageEnglish (US)
Pages (from-to)1849-1856
Number of pages8
JournalAnticancer Research
Volume15
Issue number5 B
StatePublished - Dec 1 1995

Fingerprint

Selenium
Poisons
Feces
Cyanates
Urine
selenocyanic acid
benzyl selenocyanate
Gastrointestinal Tract
Neoplasms
Animal Models

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{c57a6ad13be8426c9e54647662bee286,
title = "Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds",
abstract = "We previously demonstrated that while both benzyl selenocyanate (BSC) and 1,4- phenylenebis(methylene)selenocyanate (p-XSC) have high efficacy as cancer chemo-preventive agents in several animal tumor models, p-XSC is less toxic. Using atomic absorption spectophotometry, we compared the urinary and fecal excretion of total selenium derived from pXSC and BSC in female CD rats. The results indicate that there exist distinct differences in the selenium excretion patterns when these compounds are administered orally, but not when they are administered ip. In terms of the percent dose, the total selenium excreted in the 5 days following equimolar dosing (50 μmol/ikgl of p-XSC or BSC, respectively, was as follows: after gavage, 68{\%} or 3{\%} in the feces and 6{\%} or 18{\%} in the urine; after ip. administration, 9{\%} or 4{\%} in feces and 16{\%} or 20{\%} in urine. These results indicate that while most of the BSC administered orally is absorbed in the gastrointestinal tract, most of the p-XSC given the same way is not absorbed. This difference would account for the significantly lower tissue levels of selenium derived from orally administered p-XSC compared to BSC, and accounts, in part, for the lower oral toxicity of p-XSC compared to BSC. Subsequent studies employing o- and m-XSC, isomers of p-XSC, demonstrate that the excretion patterns of selenium are significantly different, depending on the position of substitution. In vitro studies suggest that the differences among BSC and the three XSC isomers with regard to absorption is probably due to different extent of binding to components of the gut contents. The results of these studies are useful for the future design of less toxic and more effective chemo-preventive organic seleno-cyanates.",
author = "Sohn, {O. S.} and H. Li and A. Surace and Karam El-Bayoumy and P. Upadhyaya and Fiala, {E. S.}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "15",
pages = "1849--1856",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds. / Sohn, O. S.; Li, H.; Surace, A.; El-Bayoumy, Karam; Upadhyaya, P.; Fiala, E. S.

In: Anticancer Research, Vol. 15, No. 5 B, 01.12.1995, p. 1849-1856.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds

AU - Sohn, O. S.

AU - Li, H.

AU - Surace, A.

AU - El-Bayoumy, Karam

AU - Upadhyaya, P.

AU - Fiala, E. S.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - We previously demonstrated that while both benzyl selenocyanate (BSC) and 1,4- phenylenebis(methylene)selenocyanate (p-XSC) have high efficacy as cancer chemo-preventive agents in several animal tumor models, p-XSC is less toxic. Using atomic absorption spectophotometry, we compared the urinary and fecal excretion of total selenium derived from pXSC and BSC in female CD rats. The results indicate that there exist distinct differences in the selenium excretion patterns when these compounds are administered orally, but not when they are administered ip. In terms of the percent dose, the total selenium excreted in the 5 days following equimolar dosing (50 μmol/ikgl of p-XSC or BSC, respectively, was as follows: after gavage, 68% or 3% in the feces and 6% or 18% in the urine; after ip. administration, 9% or 4% in feces and 16% or 20% in urine. These results indicate that while most of the BSC administered orally is absorbed in the gastrointestinal tract, most of the p-XSC given the same way is not absorbed. This difference would account for the significantly lower tissue levels of selenium derived from orally administered p-XSC compared to BSC, and accounts, in part, for the lower oral toxicity of p-XSC compared to BSC. Subsequent studies employing o- and m-XSC, isomers of p-XSC, demonstrate that the excretion patterns of selenium are significantly different, depending on the position of substitution. In vitro studies suggest that the differences among BSC and the three XSC isomers with regard to absorption is probably due to different extent of binding to components of the gut contents. The results of these studies are useful for the future design of less toxic and more effective chemo-preventive organic seleno-cyanates.

AB - We previously demonstrated that while both benzyl selenocyanate (BSC) and 1,4- phenylenebis(methylene)selenocyanate (p-XSC) have high efficacy as cancer chemo-preventive agents in several animal tumor models, p-XSC is less toxic. Using atomic absorption spectophotometry, we compared the urinary and fecal excretion of total selenium derived from pXSC and BSC in female CD rats. The results indicate that there exist distinct differences in the selenium excretion patterns when these compounds are administered orally, but not when they are administered ip. In terms of the percent dose, the total selenium excreted in the 5 days following equimolar dosing (50 μmol/ikgl of p-XSC or BSC, respectively, was as follows: after gavage, 68% or 3% in the feces and 6% or 18% in the urine; after ip. administration, 9% or 4% in feces and 16% or 20% in urine. These results indicate that while most of the BSC administered orally is absorbed in the gastrointestinal tract, most of the p-XSC given the same way is not absorbed. This difference would account for the significantly lower tissue levels of selenium derived from orally administered p-XSC compared to BSC, and accounts, in part, for the lower oral toxicity of p-XSC compared to BSC. Subsequent studies employing o- and m-XSC, isomers of p-XSC, demonstrate that the excretion patterns of selenium are significantly different, depending on the position of substitution. In vitro studies suggest that the differences among BSC and the three XSC isomers with regard to absorption is probably due to different extent of binding to components of the gut contents. The results of these studies are useful for the future design of less toxic and more effective chemo-preventive organic seleno-cyanates.

UR - http://www.scopus.com/inward/record.url?scp=0029611048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029611048&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 1849

EP - 1856

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -